scholarly journals Bone health in cancer patients - An important clinical issue

2017 ◽  
Vol 26 (6) ◽  
pp. e12791
Author(s):  
David Weller ◽  
Aristotelis Bamias
Keyword(s):  
Cancer Patients ◽  
Bone Health ◽  
Clinical Issue ◽  
Important Clinical Issue

Bone health and its correlates in Korean prostate cancer patients receiving androgen deprivation therapy

2016 ◽  
Vol 21 ◽  
pp. 197-204
Author(s):  
Soo Hyun Kim ◽  
Do Hwan Seong ◽  
Sang Min Yoon ◽  
Young Deuk Choi ◽  
Youngkyu Song ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Bone Health ◽  
Androgen Deprivation

Abstract 2162: Prior bone health history in breast cancer patients on aromatase inhibitors

2014 ◽  
Author(s):  
Marilyn L. Kwan ◽  
Joan C. Lo ◽  
Li Tang ◽  
Cecile Laurent ◽  
Janise M. Roh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Aromatase Inhibitors ◽  
Bone Health ◽  
Breast Cancer Patients ◽  
Health History

scholarly journals Bone health management in early breast cancer patients: an Italian Osteoncology Center experience

2017 ◽  
Vol 28 ◽  
pp. vi25-vi26
Author(s):  
F. Recine ◽  
A. Bongiovanni ◽  
V. Fausti ◽  
L. Mercatali ◽  
N. Riva ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Bone Health ◽  
Health Management ◽  
Breast Cancer Patients

scholarly journals Bone health in cancer patients: ESMO Clinical Practice Guidelines

2014 ◽  
Vol 25 ◽  
pp. iii124-iii137 ◽  
Author(s):  
R. Coleman ◽  
J.J. Body ◽  
M. Aapro ◽  
P. Hadji ◽  
J. Herrstedt
Keyword(s):  
Clinical Practice ◽  
Cancer Patients ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Bone Health

Impact of endocrine therapy on serum cortisol levels in breast cancer patients and its possible link to bone health

2020 ◽  
Author(s):  
V Falcone ◽  
E Reiser ◽  
L Grula ◽  
H Blasch ◽  
G Pfeiler
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Bone Health ◽  
Serum Cortisol ◽  
Breast Cancer Patients ◽  
Cortisol Levels

Dialysis Access: An Increasingly Important Clinical Issue

2009 ◽  
Vol 32 (12) ◽  
pp. 851-856 ◽  
Author(s):  
Maurizio Gallieni ◽  
Alma Martini ◽  
Nicoletta Mezzina
Keyword(s):  
Dialysis Access ◽  
Clinical Issue ◽  
Important Clinical Issue

scholarly journals Dual Actions of Ketorolac in Metastatic Ovarian Cancer

Cancers ◽  
2019 ◽  
Vol 11 (8) ◽  
pp. 1049 ◽  
Author(s):  
Hudson ◽  
Cook ◽  
Grimes ◽  
Muller ◽  
Adams ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Inflammatory Responses ◽  
Residual Disease ◽  
Disease Recurrence ◽  
Racemic Mixture ◽  
Clinical Issue ◽  
Anti Cancer ◽  
Simultaneous Inhibition ◽  
Inflammatory Drugs

Cytoreductive surgery and chemotherapy are cornerstones of ovarian cancer treatment, yet disease recurrence remains a significant clinical issue. Surgery can release cancer cells into the circulation, suppress anti-tumor immunity, and induce inflammatory responses that support the growth of residual disease. Intervention within the peri-operative window is an under-explored opportunity to mitigate these consequences of surgery and influence the course of metastatic disease to improve patient outcomes. One drug associated with improved survival in cancer patients is ketorolac. Ketorolac is a chiral molecule administered as a 1:1 racemic mixture of the S- and R-enantiomers. The S-enantiomer is considered the active component for its FDA indication in pain management with selective activity against cyclooxygenase (COX) enzymes. The R-enantiomer has a previously unrecognized activity as an inhibitor of Rac1 (Ras-related C3 botulinum toxin substrate) and Cdc42 (cell division control protein 42) GTPases. Therefore, ketorolac differs from other non-steroidal anti-inflammatory drugs (NSAIDs) by functioning as two distinct pharmacologic entities due to the independent actions of each enantiomer. In this review, we summarize evidence supporting the benefits of ketorolac administration for ovarian cancer patients. We also discuss how simultaneous inhibition of these two distinct classes of targets, COX enzymes and Rac1/Cdc42, by S-ketorolac and R-ketorolac respectively, could each contribute to anti-cancer activity.

Sign in / Sign up

Export Citation Format

Share Document